While most preclinical studies on CXCR3 ligand–targeting therapeutic compounds indicate that CXCR3 ligand expression promotes the recruitment of CXCR3+ CD4+ and CD8+ T cells to the tumor site, other studies have suggested that this is not the case. The gene discussed is CD4; the disease is neoplasm.